Cortica Announces $60 Million Financing to Accelerate National Access to Comprehensive Autism Care Model  | Circa June 29, 2021 #NotAnAutisticAlly #BanABA

[Note: Shared for #AutisticHistory archive purposes. This is NOT An Autistic Ally.]

Cortica Announces $60 Million Financing to Accelerate National Access to Comprehensive Autism Care Model


The Series C was led by Longitude Capital and adds board members Adam Boehler and Martha Temple

SAN DIEGO, June 29, 2021 /PRNewswire/ —Cortica, Inc. (“Cortica”), a leader in technology-enabled clinical services for autism and other neurodevelopmental conditions, announced today a $60 million financing to further its mission to transform autism care. Longitude Capital led the oversubscribed Series C round with participation from new investors .406 Ventures and Adam Boehler, along with existing investors Questa Capital and Aperture Venture Partners. Silicon Valley Bank also participated by expanding Cortica’s credit facilities. Cortica is led by co-founders Neil Hattangadi, M.D., CEO, and Suzanne Goh, M.D., BCBA, Pediatric Neurologist and Chief Medical Officer, both Rhodes scholars who met at Harvard Medical School.

Cortica is accelerating its already rapid growth, expanding centers across multiple states, and investigating novel drug, device, and diagnostic technologies through sponsored and NIH-funded research. Cortica is considered a leader in autism outcomes research, having conducted multiple clinical studies to demonstrate the therapeutic benefits and cost-effectiveness of its evidence-based platform. “I am honored to have investors and board members with a proven record of success and an unwavering commitment to helping children with neurodevelopmental differences,” said Dr. Neil Hattangadi. “These partners will help us accelerate the rollout of our autism care centers nationally, as well as support ongoing innovation for clinical care delivery and the family experience.”

“Cortica’s revolutionary technology-enabled care model provides families with a comprehensive diagnosis inclusive of genetic, metabolic, and neurophysiologic causes paired with coordinated, multidisciplinary therapies to improve a child’s sensorimotor processing, medical comorbidities, communication, and socialization,” said Michael Wert of Longitude Capital and new Cortica board member. “We look forward to supporting the Cortica team in its expansion of this holistic, patient-centric approach.”

As part of the financing, Cortica is pleased to announce the addition of two industry leaders to its board of directors: Adam Boehler, CEO of Rubicon Founders, founder of Landmark Health, and former director of the Center for Medicare and Medicaid Innovation (CMMI); and Martha Temple, former CEO of Optum Behavioral Health and market president at Aetna.

“After 30 years as a payer executive, I recognize the radical common sense of integrating behavioral, developmental, and medical care as Cortica does so well in autism care,” said Martha Temple. “By leveraging technology and thoughtfully coordinating care, Cortica has demonstrated impressive outcomes across multiple domains, incredibly high member satisfaction, and a commitment to driving down utilization by delivering only the appropriate therapies for each clinical challenge.”

“I’ve spent my academic career studying autism – from genetics, metabolomics, and functional imaging, to enhancing communication and literacy in children. This research, along with Neil’s and my core beliefs that empowering children with neurodevelopmental differences is a human rights issue and that their families deserve tremendous hope and joy in their lives, have built Cortica and will continue to drive our future,” said Dr. Suzanne Goh.

About Cortica Inc.
We’re on a mission to revolutionize healthcare for children with autism and other neurodevelopmental differences. Cortica was founded to fix the fragmented journey families typically navigate while seeking diagnoses and therapies for their children. To bring our vision to life, we seamlessly blend neurology, research-based therapies, and technology into comprehensive care programs for the children we serve. Our coordinated approach leads to best-in-class member satisfaction and empowers families to achieve long-lasting, transformative results. For more information, please visit

About Longitude Capital
Longitude Capital is a leading healthcare venture capital firm that invests in transformative biotechnology, medical technology and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. Founded in 2006, Longitude Capital invests in both privately held and publicly traded companies through a variety of investment approaches. Longitude Capital has offices in Menlo Park, CA, Greenwich, CT, and Boston, MA. For more information, please visit or LinkedIn.

Media Contact:
Cassie Walker
Head of Marketing, Cortica
(858) 252-4582


Autistic people have fought the inclusion of ABA in therapy for us since before Autism Speaks, and other non-Autistic-led autism organizations, started lobbying legislation to get it covered by insurances and Medicaid. 

ABA is a myth originally sold to parents that it would keep their Autistic child out of an institution. Today, parents are told that with early intervention therapy their child will either be less Autistic or no longer Autistic by elementary school, and can be mainstreamed in typical education classes. ABA is very expensive to pay out of pocket. Essentially, Autism Speaks has justified the big price tag up front will offset the overall burden on resources for an Autistic’s lifetime. The recommendation for this therapy is 40 hours a week for children and toddlers.

The original study that showed the success rate of ABA to be at 50% has never been replicated. In fact, the study of ABA by United States Department of Defense was denounced as a failure. Not just once, but multiple times. Simply stated: ABA doesn’t workIn study after repeated study: ABA (conversion therapy) doesn’t work. 

What more recent studies do show: Autistics who experienced ABA therapy are at high risk to develop PTSD and other lifelong trauma-related conditions. Historically, the autism organizations promoting ABA as a cure or solution have silenced Autistic advocates’ opposition. ABA is also known as gay conversion therapy.

The ‘cure’ for Autistics not born yet is the prevention of birth. 

The ‘cure’ is a choice to terminate a pregnancy based on ‘autism risk.’ The cure is abortion. This is the same ‘cure’ society has for Down Syndrome. 

This is eugenics 2021. Instead of killing Autistics and disabled children in gas chambers or ‘mercy killings’ like in Aktion T4, it’ll happen at the doctor’s office, quietly, one Autistic baby at a time. Different approaches yes, but still eugenics and the extinction of an entire minority group of people.

Fact: You can’t cure Autistics from being Autistic.

Fact: You can’t recover an Autistic from being Autistic.

Fact: You can groom an Autistic to mask and hide their traits. Somewhat. … however, this comes at the expense of the Autistic child, promotes Autistic Burnout (this should not be confused with typical burnout, Autistic Burnout can kill Autistics), and places the Autistic child at high risk for PTSD and other lifelong trauma-related conditions.

[Note: Autism is NOT a disease, but a neurodevelopmental difference and disability.]

Fact: Vaccines Do Not Cause Autism.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: